STOCK TITAN
  1. Home
  2. Sec-filings
  3. TRAW
  4. [Form 4] Traws Pharma, Inc. Insider Trading Activity

Traws Pharma (TRAW) CFO receives new RSU and stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Parker Charles Nolan reported acquisition or exercise transactions in this Form 4 filing.

Traws Pharma, Inc. Chief Financial Officer Parker Charles Nolan reported multiple equity awards from the company. He received 15,393 restricted stock units that vest 100% on the first anniversary of the grant date. He was also granted stock options for 104,544 shares at $1.60, 61,571 shares at $2.33, and 32,406 shares at $3.01 per share, each vesting in full one year after the respective grant dates.

Positive

  • None.

Negative

  • None.
Insider Parker Charles Nolan
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 104,544 $0.00 --
Grant/Award Stock Option (right to buy) 61,571 $0.00 --
Grant/Award Common Stock 15,393 $0.00 --
Grant/Award Stock Option (right to buy) 32,406 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 104,544 shares (Direct); Common Stock — 15,393 shares (Direct)
Footnotes (1)
  1. Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
RSU grant 15,393 units Restricted stock units vest 100% after one year
Option grant 1 104,544 shares at $1.60 Stock options, expire in 2036
Option grant 2 61,571 shares at $2.33 Stock options, expire in 2035
Option grant 3 32,406 shares at $3.01 Stock options, expire in 2035
Post-grant option position 104,544 104,544 derivative shares Total shares following latest 1.60 option grant
Post-grant option position 61,571 61,571 derivative shares Total shares following 2.33 option grant
Post-grant stock position 15,393 shares Total common shares following RSU award
restricted stock units financial
"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock options financial
"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
2021 Incentive Compensation Plan financial
"under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof."
expiration date financial
"expiration_date": "2036-03-08T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Parker Charles Nolan
(Last)(First)(Middle)
C/O TRAWS PHARMA, INC
12 PENNS TRAIL
(Street)
NEWTOWN PENNSYLVANIA 18940
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/12/2025		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock12/12/2025A15,393(1)A$015,393D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$3.0110/12/2025A32,40610/12/2026(2)10/12/2035Common Stock32,406$032,406D
Stock Option (right to buy)$2.3312/12/2025A61,57112/12/2026(3)12/12/2035Common Stock61,571$061,571D
Stock Option (right to buy)$1.603/08/2026A104,54403/08/2027(4)03/08/2036Common Stock104,544$0104,544D
Explanation of Responses:
1. Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.
2. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
3. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
4. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
/s/ Charles N. Parker04/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Traws Pharma (TRAW) report for its CFO?

Traws Pharma’s CFO, Parker Charles Nolan, reported receiving equity awards. He was granted restricted stock units and several stock option awards, all as compensation. These transactions increase his potential ownership but do not involve any open-market buying or selling of TRAW shares.

How many restricted stock units did the Traws Pharma CFO receive?

Parker Charles Nolan received 15,393 restricted stock units. According to the disclosure, these units vest 100% on the first anniversary of the grant date, and each unit converts into one share of Traws Pharma common stock upon vesting, aligning his compensation with shareholder value.

What stock option grants did the Traws Pharma (TRAW) CFO receive and at what prices?

The CFO received stock options over 104,544 shares at $1.60, 61,571 shares at $2.33, and 32,406 shares at $3.01 per share. All options were granted at a zero-cost award price but have specified exercise prices if he chooses to purchase the underlying common shares later.

When do the new Traws Pharma CFO stock options expire?

The reported stock options have long-dated expirations. The 104,544-share grant at $1.60 expires in 2036, while the 61,571-share grant at $2.33 and the 32,406-share grant at $3.01 both expire in 2035, providing extended exercise windows for the CFO.

How do the equity awards to the Traws Pharma CFO vest?

Both the restricted stock units and the stock options vest 100% on the first anniversary of each grant date. This means the CFO must remain in position through that one-year period to receive the full benefit, supporting retention and long-term alignment with Traws Pharma shareholders.

Were the Traws Pharma CFO’s equity awards part of a company compensation plan?

Yes. The filing states the stock options were awarded under Traws Pharma’s 2021 Incentive Compensation Plan by the compensation committee of independent directors. This indicates the grants are structured compensation rather than discretionary market purchases of TRAW stock.